Evidence map›Paper›PMID 36427875›Full record

ArticleClinical medicine (London, England)2022

Using NEWS2: an essential component of reliable clinical assessment.

John Welch, John Dean, Jillian Hartin

Registry-linked trialAbstract read
In one paragraph

Article in Clinical medicine (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04347239 (A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04347239 phase2completednot on this map

A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

TypeinterventionalSponsorCytoDyn, Inc.Ran2020 to 2022Enrolled484ConditionsCoronavirus Disease 2019ArmsPlacebo, Leronlimab (700mg)
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Early bedside risk stratification using Charlson comorbidity index and NEWS2 in adults hospitalized with respiratory syncytial virus infection: a multicentre cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

John WelchUniversity College London Hospitals NHS Foundation Trust, London, UK and national clinical advisor for acute deterioration, NHS England, London, UK.
John DeanEast Lancashire Hospitals NHS Trust, Blackburn, UK and clinical vice president, Royal College of Physicians, London, UK; john.dean@rcp.ac.uk.
Jillian HartinUniversity College London Hospitals NHS Foundation Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The National Early Warning Score 2 (NEWS2) is the established track and trigger system to assess illness severity and risk of deterioration for patients in acute episodes of care in the UK. It is also increasingly used internationally. In this article, we outline established and recommended practice for initial and ongoing assessment. We also highlight where practice may not meet these standards, how the full context and assessment of the patient is paramount, and opportunities for more accurate assessment in the future.

Indexed as

Clinical DeteriorationLongitudinal StudiesHumansSeverity of Illness Indexclinical assessmentdeteriorationmonitoringNEWS2

Identifiers

PMID36427875
PMCPMC9761428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.